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A B S T R A C T
Objectives: This study sought to assess the cost-effectiveness of bivalirudin versus heparin
plus glycoprotein IIb/IIIa inhibitor (GPI) in thienopyridine-treated non–ST-segment eleva-
tion acute coronary syndrome (NSTE-ACS) patients undergoing early or urgent invasive
management, from a United Kingdom National Health Service perspective.
Methods: A decision-analytic model with lifelong time horizon was populated with event risks
and resource use parameters derived from the Acute Catheterization and Urgent Intervention
Triage Strategy (ACUITY) trial raw data. In a parallel analysis, key comparator strategy inputs
came from Global Registry of Acute Coronary Events (GRACE) patients enrolled in the United
Kingdom. Upstream and catheter laboratory-initiated GPI were assumed to be tirofiban and
abciximab, respectively. Life expectancy of first-year survivors, unit costs, and health-state
utilities came from United Kingdom sources. Costs and effects were discounted at 3.5%. Incre-
mental cost-effectiveness ratios (ICERs) were expressed as cost per quality-adjusted life year
(QALY) gained.
Results: Higher acquisition costs for bivalirudin were partially offset by lower hospitaliza-
tion and bleeding costs. In the ACUITY-based analysis, per-patient lifetime costs in the
bivalirudin and heparin plus GPI strategies were £10,903 and £10,653, respectively. Patients
survived 10.87 and 10.82 years on average, corresponding to 5.96 and 5.93 QALYs and result-
ing in an ICER of £9,906 per QALY gained. The GRACE-based ICER was £12,276 per QALY
gained. In probabilistic sensitivity analysis, 72.1% and 67.0% of simulation results were more
cost-effective than £20,000 per QALY gained, in the ACUITY-based and GRACE-based anal-
yses, respectively. Additional scenario analyses implied that greater cost-effectiveness may
be achieved in actual clinical practice.
Conclusions: Treating NSTE-ACS patients undergoing invasive management with bivaliru-
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25V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3din is likely to represent a cost-effective option for the United Kingdom, when compared
with the current practice of using heparin and a GPI.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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n patients with non–ST-segment elevation acute coronary
yndromes (NSTE-ACS), antiplatelet therapy and early inva-
ive management have substantially reduced ischemia-re-
ated morbidity and mortality. This reduction has been
chieved at a higher risk of bleeding complications. Bi-
alirudin, a direct and specific thrombin inhibitor, repre-
ents an alternative to anticoagulation and platelet inhibi-
ion with heparin and glycoprotein IIb/IIIa inhibitor (GPI). The
cute Catherization and Urgent Intervention Triage Strategy
ACUITY) trial, a large, multicenter, prospective, randomized,
pen-label, parallel-group, phase III trial, established the com-
arative clinical efficacy and safety of bivalirudin in patients
ith moderate- to high-risk NSTE-ACS [1]. In the overall ACUITY
opulation, bivalirudin was associated with similar rates of
schemia and significantly reduced bleeding when compared
ith heparin plus GPI (H-GPI) [1,2]. In registration trials of
lanned percutaneous coronary intervention (PCI) and acute
yocardial infarction (MI), bivalirudin showed similar results
nd trended to improved mortality [3–5]. Such a trend was also
vident in the ACUITY patients who received a thienopyridine
efore or after PCI [2]. On this basis, the European Medicines
gency recently approved bivalirudin for patients with NSTE-
CS [6]. Coadministration of a thienopyridine is a conditional
lement of this approval.
It remains unclear which groups of NSTE-ACS patients in
he United Kingdom can benefit most from bivalirudin, and
ealth economic implications remain to be determined.
ealth economic evaluation studies based on data from
ultinational randomized clinical trials may not suffi-
iently take into account local epidemiological and clinical
ractice patterns. Local registry data can be used to over-
ome such limitations of external validity, albeit sometimes
t the cost of compromising internal validity. The Global
egistry of Acute Coronary Events (GRACE) is a large-scale,
ultinational, observational study of ACS patients, with
ontinuous recruitment from 1999 to 2007 [7]. In the United
ingdom, four GRACE centers recruited 4403 patients and
ncluded a subpopulation with qualifying characteristics
imilar to the ACUITY population. Bivalirudin was not used
n these patients.
Health economic evaluation studies compare costs and
linical effects of treatment strategies of interest against al-
ernatives ideally representing current best practice. Where
he treatment strategy of interest is more costly and also more
linically favorable than the comparator, an incremental cost-
ffectiveness ratio (ICER) is calculated as the quotient of the
ost difference between strategies and the difference in clini-
al effect between strategies ( cost /  effect). This work stud-
ed the incremental cost and cost-effectiveness of bivalirudin
ersus H-GPI in patients with NSTE-ACS from the perspective af the United Kingdom National Health Service (NHS). We re-
uced the problem of compromised external or internal valid-
ty by performing two parallel analyses, the first predomi-
antly based on ACUITY and only making few key
djustments to reflect United Kingdom practice characteris-
ics, the second using the United Kingdom GRACE registry
opulation.
ethods
verview and patient population
model-based cost-utility analysis with a lifelong time hori-
on evaluated the health economic end point of incremental
ost per quality-adjusted life year (QALY) gained. Cost-utility
nalysis follows the cost-effectiveness approach but ex-
resses clinical effect as survival time adjusted for health-
elated quality of life. Quality of life weights (utilities) are
ained from preference-based instruments, and are defined
n a linear scale in which 1 represents perfect health and 0
epresents death. In this analysis, the population of interest
as defined as acute NSTE-ACS patients at a medium to high
isk of major cardiovascular events. Patients had to be
lanned for early or urgent invasive management, i.e., diag-
ostic angiography within 72 hours from admission followed
y PCI, coronary artery bypass graft (CABG) surgery, or conser-
ative treatment, and had to receive thienopyridine before or
fter angiography.
In the ACUITY-based analysis, absolute and relative clini-
al event risks and most other model inputs were derived
rom the raw data of the H-GPI and bivalirudin-alone arm pa-
ients who fulfilled the thienopyridine criterion (Fig. 1). Re-
aining life expectancy and long-term cardiovascular treat-
ent costs of first-year survivors, unit costs, and utilities were
rawn from published United Kingdom sources. The strate-
ies compared were those defined in the trial, i.e., H-GPI (with
PI started upstream before angiography or initiated in the
atheter laboratory if the patient was triaged to receive PCI)
nd bivalirudin alone (with the possibility of provisional, cath-
ter laboratory-induced GPI use) [1]. Fifty percent of H-GPI
atients were randomized to upstream GPI. In conse-
uence, 81% of H-GPI patients actually received GPI, and
0% of these received it upstream. Eptifibatide use was sub-
tantial in ACUITY, but in order to reflect approved indications
nd current United Kingdom practice, we assumed upstream
PI use to be tirofiban and catheter laboratory-initiated or pro-
isional use to be abciximab. A GPI class effect was assumed;
herefore, clinical event risks were not adjusted.
To select a population with a similar risk profile for the
RACE-based analysis, GRACE patients were included if they
ad ACS but no acute ST-segment elevation MI, diagnostic
ngiography within 72 hours from admission, and 6-month
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26 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3ollow-up (Fig. 1). In the interest of sample size, the exclusion
riterion of no thienopyridine use was dropped. Absolute
vent risks and key medical resource use parameters (GPI use,
ength of stay) in the comparator strategy were drawn from
RACE. The other model inputs, inclusive of relative event
isks in the bivalirudin strategy and assumptions on GPI sub-
tances used, were the same as in the ACUITY-based analysis.
hereas an identical bivalirudin strategy was modeled, the
omparator strategy in the GRACE-based analysis represented
routine practice mix of 29% H-GPI and 71% heparin alone
se. As the proportion of upstream GPI use could not be ex-
racted from the GRACE database, an assumption of 80%
ownstream use and 20% upstream use was made (unpub-
ished Myocardial Ischaemia National Audit Project data).
Baseline characteristics of the eligible ACUITY and GRACE pa-
ients and initial treatment decisions were remarkably similar al-
hough time from admission to catheterization was longer in
RACE (Table 1). No relevant differences in baseline characteristics
etween the ACUITY study arms were noted (details not shown).
odel structure
decision tree model was complemented with a Markov mod-
le to cover long-term survival (Fig. 2). Virtual patient cohorts
ere followed from primary hospitalization to death. Initial an-
iography was performed on all patients, who were then triaged
o receive PCI, CABG, or medical management. Between this ini-
ial treatment and end of the first year, patients could experience
ajor and minor bleeding (until day 30), acute MI, or repeat re-
ascularization, or die. Stroke events, which were rare in
CUITY and evenly distributed between study arms, were not
aken into account. After the first year, survival was modeled
Basis for data derivaons 
from ACUITY dataset
Full ACUITY populaon
(N = 13, 819)
Enrolled in heparin plus GPI 
and bivalirudin alone arms
(N = 9,215)
Received a thienopyridine prior 
to or post angiography/PCI
(N = 7,523),
of which
Heparin plus GPI arm
(N = 3,730)
Bivalirudin alone arm
(N = 3,793)
ig. 1 – Patient basis for derivation of model inputs. GPI, glyc
yocardial infarction; NSTE-ACS, non–ST-segment elevation
ntervention; UK, United Kingdom.ased on published life expectancies. The Markov module used bwo disease stages (alive/dead) and a cycle length of 1 year. A
alf-cycle correction was used for costs as well as effects. As
imulated cohorts moved through the model, QALYs, medical
esource use, and costs were accumulated. In the base case
nalyses, costs and effects were discounted at 3.5% as rec-
mmended by the UK National Institute for Health and Clin-
cal Excellence [8].
odel inputs
linical event risks
CUITY-based and GRACE-based comparator strategy event
isks, and ACUITY-based relative event risks in the bivalirudin
trategy, are shown in Table 2. GRACE-based risks were adjusted
or differential follow-up times to enable ACUITY-based relative
isks to be applied. CABG-related bleeding was disregarded in
oth analyses. The GRACE definition of major bleeding was
lightly stricter than the ACUITY definition [9,10].
ong-term patient survival
ased on Nottingham Heart Attack Register data, Palmer et al.
stimated the average life expectancy of 6-month ACS survi-
ors to be 9.65 years [11]. We corrected this value for age dif-
erences between study populations based on United King-
om life-tables and the Declining Exponential Approximation
f Life Expectancy method [12,13]. The resulting estimates of
0.39 years for the ACUITY-based analysis and of 10.71 years
or the GRACE-based analysis were converted to Markov tran-
ition probabilities. Patients entered our Markov module at 1
ear, but in light of potentially increased life expectancy at-
ributable to medical progress after the Nottingham Heart At-
ack Register data were collected, and as 1-year survivors may
Paents with NSTE-ACS 
(no acute STEMI)
(N = 3,549)
Basis for data derivaons 
from GRACE UK dataset
Full GRACE UK populaon
(N = 4,399)
Six-month follow-up data 
available
(N = 3,971)
Diagnosc angiography within 
72 hours from admission
(N = 557)
tein IIb/IIIa inhibitor; STEMI, ST-segment elevation
te coronary syndrome; PCI, percutaneous coronaryopro
acue healthier on average than 6-month survivors, no additional
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27V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3orrection for this difference was applied. Long-term survival
f 1-year survivors was assumed to be independent of the
nitial anticoagulation strategy.
ig. 2 – Structure of decision analytic model. Model nodes (c
ubstructures. For example, the structure to the right of the
lone 1 is reused for the Heparin + GPI strategy. Anticoagula
sing an indicator variable for anticoagulation strategy, and
se of relative event risks as required. Differential clinical ef
onservative treatment) could be implemented in the same
Table 1 – Baseline and initial treatment characteristics.
Characteristic ACUITY p
N
Age, mean year  SD 7523
Weight, mean kg  SD 7518
Female, patients (%) 7523
Diabetes, patients (%) 7472
Elevated cardiac biomarkers, patients (%) 6970
ST-segment deviation 1 mm, patients (%) 7520
GRACE risk score [35], mean  SD 1265
Time from admission to angiography, median
hour
7486
PCI, patients (%) 7523
CABG, patients (%) 7523
Thienopyridine use, patients (%) 7523
CABG, coronary artery bypass graft; CK, creatinine kinase; CK-MB, crea
coronary syndrome; PCI, percutaneous coronary intervention; SD, sta
* Basis for ACUITY-based cost-effectiveness analysis.
† Basis for GRACE-based cost-effectiveness analysis.
‡ For 103 ACUITY patients enrolled in UK, mean  SD, 79.9  13.1 kg
§ For 95 ACUITY patients enrolled in UK, frequency (%), 15 (15.8).
 GRACE criterion: 2 upper limit of normal of CK-MB or, if not ava
increase.
¶ Assuming Killip class 1. Score calculation impossible for many patxtensive subgrouping and to contain statistical uncertainty.tilities
e used European Quality of Life-5 Dimensions-based health-
tate utility weights drawn from a study of 229 consecutive MI
) denoted as clones indicate the use of identical
ost thick line (denoted as bivalirudin) defines clone 1.
strategy-specific behavior of the model is achieved by
ulae dependent hereon. This allows, e.g., to trigger the
as a function of primary treatment strategy (PCI, CABG, or
However, this possibility was not used in order to avoid
nts* GRACE UK NSTE-
ACS patients with
diagnostic
angiography
within 72 hours†
All GRACE UK
NSTE-ACS patients
N N
11.5 557 61.3  10.9 3542 64.7  12.0
18.3‡ 504 78.6  15.3 2766 78.1  16.7
(29.0) 557 161 (28.9) 3544 1217 (34.3)
(28.1)§ 556 87 (15.6) 3538 527 (14.9)
(61.1) 527 269 (51.0) 3406 1387 (40.7)
(34.7) 557 188 (33.8) 3549 1160 (32.7)
29¶ 487 117  30 3185 122  34
9.7 557 27.5 958 59.1
(66.8) 557 362 (65.0) 3549 893 (25.2)
(7.9) 557 50 (9.0) 3549 54 (4.6)
(100.0) 557 490 (88.0) 3549 1972 (55.6)
e kinase isoenzyme MB; NSTE-ACS, non–ST-segment elevation acute
d deviation; UK, United Kingdom.
, of CK or upper limit of normal of troponin. ACUITY criterion: any
because of missing heart rate and blood pressure data.ircles
leftm
tion
form
fects
way.atie
62.6 
85.5 
2179
2098
4255
2610
112 
1
5026
591
7523
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28 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3urvivors discharged from a United Kingdom center [14]. The
uthors assessed self-perceived health status at fixed time
oints post discharge, irrespective of clinical event occur-
ence, and provided average results. We assumed the 6-week
verage of 0.68 to represent the situation in the first year after
he event, and the 1-year average of 0.72 to represent the sit-
ation in subsequent years. Valuation used the standard
nited Kingdom time trade-off value set, and results were
omparable to United Kingdom estimates for patients under-
oing PCI [15].
edical resource use
nticoagulant use was modeled for the initial hospitalization
eriod, based on the frequencies of use observed in ACUITY and
RACE (Table 3). Duration of administration and amount of drug
as only available from ACUITY. Unfractionated heparin was
isregarded because of its low cost. Noninteger numbers of GPI
nd bivalirudin vials were increased to the next integer to cover
aste of leftovers.
Days in normal ward and in intensive care unit (ICU)/coro-
ary care unit (CCU) during the initial hospitalization (Table 3)
ere assessed from ACUITY, irrespective of patient country of
rigin. This was justified by a very similar length of stay in the
CUITY H-GPI arm (mean  SD, 5.1  2.9 day) and in GRACE
mean  SD, 4.9  1.9 day).
Other resource items or influential drivers of resource
se in the first year included diagnostic angiographies, re-
eat revascularization procedures (PCI or CABG), and clini-
al events. PCI was used in 82% and 88% of repeat revascu-
arizations in ACUITY and GRACE, respectively. After the
rst year, long-term, cardiovascular-related medical re-
ource use was represented by a literature-derived mone-
ary amount.
nit costs
nit costs for the year 2007/2008 were drawn from United
Table 2 – Absolute and relative event risks.
Parameter ACUITY patients, H-G
arm
N Patients
(%; 95% CI
Non-CABG-related major bleed† 3730 216 (5.8; 5.1–6.6
Non-CABG-related minor bleed 3730 873 (23.4; 22.1–2
MI§ 3730 258 (6.9; 6.1–7.8
Repeat or unplanned revascularization 3730 342 (9.2; 8.3–10.
Death 3730 136 (3.6; 3.1–4.3
CABG, coronary artery bypass graft; CI, confidence interval; GPI, glyc
available; NSTE-ACS, non–ST-segment elevation acute coronary synd
* Based on comparison of event risks in ACUITY at different time po
other event risks in GRACE were adjusted to represent 1-year risk.
† The GRACE definition of major bleeding was slightly stricter than t
‡ Not recorded in GRACE, therefore estimated on a pro-rata basis.
§ Information on MI occurrence available in GRACE from 2002 on. Th
 In GRACE patients enrolled from 2002 on, the estimated risk of deaingdom sources or sources for England and Wales (Table 3). shen necessary, older unit costs were inflated to 2007/2008
rices [16]. Drug prices were 2008 prices and remained un-
hanged in 2009 [17].
Unit costs for MI, PCI, and CABG were based on Health-
are Resource Group (HRG)– based NHS reference costs
18,19]. Double-counting of ward costs during the initial
ospitalization period was avoided by estimating PCI and
ABG procedure costs from the HRG costs on a pro-rata
asis. We used a nonward cost proportion of 55% for PCI [20]
nd a cost proportion of 30% incurred in theater in cardiac
urgery for CABG [21]. Non-Q-wave MIs occurring after ini-
ial hospitalization discharge were assumed to cost 31% of a
-wave MI [22]. The costs of MIs during the initial hospital-
zation were covered by ward, angiography, PCI, and CABG
osts.
The cost impact of ACS-treatment–related and PCI-related
leeding are partially attributable to their influence on length
f stay [23]. This element was covered by modeling initial hos-
italization ward costs; the ward costs of a small number of
leeds occurring after the initial hospitalization period were
isregarded. Additional examination and procedure costs of
n ACUITY major bleed were estimated to be 75% of the pro-
edure cost of a repeat PCI [24–26]. Transfusion costs were not
dded to avoid double-counting. Minor bleeds were assumed
o cost 6% of a major bleed [24].
Ward costs were based on NHS reference costs [18,27]. Be-
ause cardiology ward costs might be influenced by procedure
osts, the cost per day in general medicine was used as the unit
ost for a normal ward day. The cost of an ICU day and a CCU day
ere averaged to represent the unit cost of an ICU/CCU day.
Long-term annual cardiovascular treatment costs of NSTE-
CS survivors were estimated from a published model of
hrombolysis versus primary PCI in MI patients, in the absence
f NSTE-ACS–specific data [28]. Bravo Vergel et al. [28] showed
ow the remaining lifetime of 6-month MI survivors in the
nited Kingdom is distributed between a well state, a re-MI
GRACE UK NSTE-ACS
patients with diagnostic
angiography within
72 hours
ACUITY patients,
bivalirudin arm compared
with H-GPI arm
N Patients
(%; 95% CI)*
N Relative event risk
(95% CI)
549 24 (4.4; 2.8–6.4) 7523 0.57; 0.46–0.71
N/A 96 (17.7; 11.2–25.6)‡ 7523 0.59; 0.54–0.66
345 16 (4.6; 2.7–7.4) 7523 1.124; 0.96–1.32
557 73 (13.1; 10.4–16.2) 7523 1.00; 0.87–1.15
557 27 (4.8; 3.2–7.8) 7523 0.88; 0.69–1.11
ein IIb/IIIa inhibitor; H, heparin; MI, myocardial infarction; N/A, not
; UK, United Kingdom.
bleeding risks in GRACE were adjusted to represent 30-day risk and
UITY definition [9,10].
portion of Q-wave MIs in ACUITY was 113 of 553 (20.4%).
year 1 was 14 of 357 (3.9%).PI
)
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29V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3ach of these health states. Combining these elements al-
owed estimating an average annual cost.
ensitivity analysis
eterministic and probabilistic sensitivity analysis of the
ase case cost-effectiveness results was performed to as-
ess the impact of parameter uncertainty around major
odel inputs. Comparator strategy event risks, relative
vents risks, and length of stay differences between strate-
ies were varied based on 95% confidence intervals (CIs).
ariation of HRG-based unit costs made use of accompany-
ng interquartile ranges. Utility scores and estimates of the
emaining life expectancy of 1-year ACS survivors were var-
Table 3 – Medical resource use parameters and unit costs (
Parameter
Anticoagulant use, % patients
LMWH (H-GPI)
GPI (H-GPI)
Bivalirudin (bivalirudin)
GPI (provisional; bivalirudin)
Anticoagulant vial numbers, mean (95% CI)†
Enoxaparin 300 mg (H-GPI)‡
Tirofiban 12.5 mg (upstream; H-GPI)
Abciximab 10 mg (catheter laboratory; H-GPI)
Bivalirudin 250 mg (bivalirudin)
Abciximab 10 mg (provisional; bivalirudin)
Initial hospitalization, mean days (95% CI)
Normal ward (H-GPI)
Normal ward (bivalirudin)
ICU/CCU (H-GPI)
ICU/CCU (bivalirudin)
Drug costs [17]
Enoxaparin (Clexane®) 300-mg multidose vial
Abciximab (ReoPro®) 10-mg vial
Eptifibatide (Integrilin®) 20-mg/75-mg vial
Tirofiban (Aggrastat®) 12.5-mg vial
Bivalirudin (Angiomax®) 250-mg vial
Event and procedure costs
Angiography procedure cost (IQR) [19]
PCI cost (IQR) [18]
PCI procedure cost (IQR) [18,20]
CABG cost (IQR) [18]
CABG procedure cost (IQR) [18,21]
Q-wave MI (IQR) [18]
Non-Q-wave MI (IQR) [18,22]
Major bleed examination and procedure cost [18,24,25]
Minor bleed examination and procedure cost [18,24,25]
Ward costs
Normal ward day (IQR) [27]
CCU/ICU day (IQR) [18]
Long-term annual cardiovascular treatment cost of 1-year survivors
ACS, acute coronary syndrome; CABG, coronary artery bypass graft;
inhibitor; H, heparin; ICU, intensive care unit; IQR, interquartile rang
percutaneous coronary intervention.
* Including 8.5% ACUITY patients and 47.2% GRACE patients with ot
† Per applicable patient.
‡ LMWH was assumed to be enoxaparin, as in the majority of patient
technical simplicity.
§ ACUITY-based vial numbers adjusted to GRACE weight distribution
 Excluding ward costs.ed by 25%. Estimates of bleed costs and of long-term an- cual cardiovascular treatment costs were varied by50% to
eflect increased uncertainty. In probabilistic analysis,
hese ranges of variation were implemented using beta dis-
ributions for absolute event risks, lognormal distributions
or relative event risks, normal distributions for length of
tay differences, and triangular distributions for the re-
aining parameters.
Additional scenario analyses addressed applicability of the
ase case results to United Kingdom medical practice. The
roportion of upstream as opposed to catheter laboratory-in-
uced GPI use was switched from 60% to 20% in the ACUITY-
ased analysis and from 20% to 60% in the GRACE-based anal-
sis, under the simplifying assumption of no changes in
ACUITY-based
analysis
GRACE-based analysis
54.3* 70.2*
81.2 29.9
99.3 Assume same
8.7 Assume same
0.76 (0.73–0.79) 0.74 (0.70–0.77)§
1.49 (1.44–1.54) 1.47 (1.42–1.52)§
3.25 (3.20–3.29) 3.17 (3.14–3.20)§
2.17 (2.12–2.22) 2.13 (2.08–2.19)§
3.37 (3.27–3.48) 3.12 (3.06–3.17)§
3.39 (3.32–3.47) Assume same
3.27 (3.20–3.34) Assume same
1.51 (1.46–1.56) Assume same
1.44 (1.39–1.49) Assume same
22
260
14.45/45.42
146
310
268 (254–474)
2614 (2087–2955)
1438 (1148–1625)
8631 (7456–10,212)
2624 (2267–3104)
1934 (882–2376)
600 (274–737)
1,078
67
257 (251–275)
938 (777–1,060)
851
coronary care unit; CI, confidence interval; GPI, glycoprotein IIb/IIIa
WH, low molecular weight heparin; MI, myocardial infarction; PCI,
ticoagulants in addition to LMWH.
e was converted to fractions of Clexane® 300 mg multidose vials, for£).
[28]
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.linical effectiveness [29,30]. To capture change over time, the
Ga
a
G
e
i
c
d
8
b
r
c
g
v
i
f
s
a
t
b
r
t
n
o
a
d
s
d
c
e
t
0
d
a
T
D
w
t
2
l
i
R
S
I
d
t
b
C
C
T
a
c
b
a
g
£
S
D
p
r
30 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3RACE-based analysis was rerun with values for risk of death
nd overall GPI use as observed from 2002 onward. To achieve
scenario more closely aligned with ACUITY, use of individual
PIs was set to the values observed in the trial, implying 60%
ptifibatide use. A further scenario assumed initial hospital-
zation to be of equal duration in both strategies. To reflect
urrent practice in some United Kingdom centers, use of ra-
ial arterial access, which was 7% in ACUITY, was set to 30% to
0%. In this context, we conservatively assumed no access site
leeds in radial arterial access patients and correspondingly
educed length of stay differences between strategies. The oc-
urrence, relative reduction, and length of stay impact of or-
an bleeds were left unchanged. The discount rate was also
aried, from 0% to 6%.
In the United Kingdom, the use of bivalirudin is by the
nterventional cardiologist only and the typical time period
rom start of administration to angiography is likely to be
horter than in ACUITY. Therefore, in an additional explor-
tory analysis, bivalirudin use was restricted to 1 vial per pa-
ient. To maintain consistency between strategies, the num-
er of tirofiban vials in the upstream GPI situation was also
educed to 1. Abciximab use, starting in the catheter labora-
ory only, was left unchanged. The simplifying assumption of
o changes in clinical effectiveness was made. In the absence
f robust data, this was justified by an additional subgroup
nalysis of N  3464 ACUITY patients with a time from ran-
omization to start of angiography of 4 hours. Within this
ubgroup, N 1706 bivalirudin arm patients with nonmissing
rug use data had a median actual bivalirudin use of 0.6 vials,
orresponding to 1 vial taking into account waste. Relative
vent risks (95% CIs) in the bivalirudin arm were similar to
hose reported in Table 2: 0.52 (0.38–0.73) for major bleeding,
.60 (0.51–0.70) for minor bleeding, 1.22 (0.94–1.57) for myocar-
ial infarction, 1.09 (0.90–1.32) for repeat revascularization,
Table 4 – Base case cost (£ per patient; amounts represent
cost-effectiveness results.
Parameter ACU
Bivalirudin
Cost of LMWH and GPI* 76
Cost of bivalirudin 668
Cost of angiographies, PCI, and CABG† 1624
Cost of MIs after initial hospitalization 31
Cost of bleeds‡ 45
Ward cost (initial hospitalization) 2189
Total 1-year cost 4633
Long-term cardiovascular treatment cost after year 1§ 6270
Total cost§ 10,903
QALYs per patient§ 5.959
ICER (£ per QALY gained)§ 99
CABG, coronary artery bypass graft; GPI, glycoprotein IIb/IIIa inhib
molecular weight heparin; MI, myocardial infarction; PCI, percutaneo
* Cost of unfractionated heparin treated as zero.
† Procedure costs during the initial hospitalization and full costs the
‡ Examination and procedure costs of bleeds until day 30.
§ Discounted at 3.5% per year.nd 0.74 (0.51–1.08) for patient death. jechnical implementation
erivations of model inputs and related statistical analyses
ere performed in Stata MP® (Stata Corporation, College Sta-
ion, TX, USA). The model was implemented in TreeAge Pro
008 Suite® (TreeAge, Inc., Williamstown, MA, USA). Probabi-
istic sensitivity analyses used 10,000 sets of randomly drawn
nput parameters.
esults
urvival
n the ACUITY-based analysis, undiscounted survival was pre-
icted to be 10.82 years in the H-GPI strategy and 10.87 years in
he bivalirudin strategy. Corresponding results in the GRACE-
ased analysis were 10.89 and 10.95 years, respectively.
ost and cost effectiveness
ost differences between strategies and ICERs are shown in
able 4. The bivalirudin strategy was characterized by higher
nticoagulant costs but lower initial hospitalization and bleed
osts than in the H-GPI strategy. The incremental cost for the
ivalirudin strategy was £250 and £423 in the ACUITY-based
nd GRACE-based analyses, respectively, and incremental
ains were 0.025 and 0.034 QALYs, which resulted in ICERs of
9906 and £12,276 per QALY gained.
ensitivity analysis
eterministic sensitivity analysis exploring the impact of
arameter uncertainty identified no overly influential pa-
ameters. ICERs (detailed in the Appendix found at: 10.1016/
ages across all patients without and with events) and
based analysis GRACE-based analysis
H-GPI Difference Bivalirudin H-GPI Difference
390 314 71 218 147
0 668 656 0 656
1625 1 1781 1781 0
28 3 14 13 1
78 33 34 59 25
2291 102 2123 2224 101
4412 221 4679 4295 384
6241 29 6342 6303 39
0,653 250 11,021 10,598 423
5.934 0.025 6.016 5.982 0.034
12,276
, heparin; ICER, incremental cost-effectiveness ratio; LMWH, low
ronary intervention; QALY, quality-adjusted life year.
r.aver
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itor; H
us co
reafte.jval.2010.10.025.asp) remained distinctly below the thres-
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31V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3old of £20,000 per QALY gained, except when relative risk
f death was set to its upper 95% CI limit. Given a nonsig-
ificant P value of 0.283, the bivalirudin strategy necessarily
as dominated in this situation with per-patient losses of
.024 and 0.032 QALYs in the ACUITY-based and GRACE-
ased analyses, respectively, and an additional cost of £196
nd £348. In probabilistic sensitivity analysis, 7214 (72.1%)
nd 6701 (67.0%) of 10,000 simulation results were more cost-
ffectivethan£20,000perQALYgained, intheACUITY-based(Fig.3;
nd Appendix found at: 10.1016/j.jval.2010.10.025.asp) and GRACE-
ased analyses.
The additional sensitivity analyses exploring clinical and
ealth economic scenarios yielded ICERs close to or better
han £15,000 per QALY gained. The assumption of radial
rterial access use in 80% of patients led to ICERs of £12,809
nd £14,403, respectively, in the ACUITY-based and GRACE-
ased analyses. In the ACUITY-based analysis, adjusting
he proportion of catheter laboratory-initiated GPI use to-
ards higher proportional use as seen in UK practice, led to
favorable ICER of £1872 per QALY gained. Restricting biva-
irudin and tirofiban use to 1 vial per patient also led to favor-
ble results. In the ACUITY-based analysis, bivalirudin be-
ame dominant under this assumption with a per-patient
ain of 0.025 QALYs and savings of £75. In the GRACE-based
nalysis, the ICER improved to £2287 per QALY gained. Details
re shown in the Appendix found at: 10.1016/j.jval.2010.
0.025.
iscussion
e assessed the cost-effectiveness of bivalirudin versus H-
Fig. 3 – ACUITY-based analysis, probabilistic sensitiPI in NSTE-ACS patients at a medium to high risk of major Kardiovascular events and undergoing an early or urgent in-
asive management strategy, from the perspective of the
nited Kingdom NHS. Two parallel analyses were performed.
he first was predominantly based on the ACUITY trial, im-
lying high internal consistency and guideline-driven treat-
ent strategies [1] but potentially limited applicability to local
edical practice. The second made use of United Kingdom
ata from the GRACE registry, to the extent possible, and re-
ected local practice more closely but implied reduced inter-
al consistency of model inputs. Both analyses yielded ICERs
or bivalirudin well below £20,000 per QALY gained. A bivaliru-
in strategy coupled with thienopyridine use remained cost-
ffective even when subjected to extensive sensitivity analy-
es.
This result is compatible with earlier economic findings.
n a bottom-up cost study of US ACUITY patients, bivaliru-
in was less costly than H-GPI at 30 days [26]. Such an ab-
olute cost advantage was not visible in our analysis, pre-
umably due to differences in US and UK practice patterns,
esource use and cost structure. Lack of detailed economic
ata for patients enrolled outside the United States pre-
luded an in-depth comparison. However, anticoagulant
osts were higher in the bivalirudin strategy and other ini-
ial hospitalization costs were lower, in both cases. Studies
f PCI patients, based on the Randomized Evaluation in PCI
inking Angiomax to Reduced Clinical Events-2 (REPLACE-2)
rial, also showed bivalirudin to be cost-saving or dominant
24,31].
Some comments are needed to reflect the applicability of our
ndings to UK practice. We assumed upstream GPI use to be
irofiban and catheter laboratory-initiated or provisional use to
e abciximab. This reflects the approach taken in most United
analysis result. QALYs, quality-adjusted life years.vityingdom clinical centers. Under the assumption of 60% eptifi-
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32 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 - 3 3atide use, cost-effectiveness was also maintained. In the ACU-
TY-based analysis, upstream GPI use, implying relatively low-
ost tirofiban or eptifibatide, was proportionally higher than in
K practice, which disfavored bivalirudin. In UK practice, biva-
irudin is predominately initiated in the catheter laboratory and
ypical use is expected to be 1 vial per patient. In the absence of
obust data on clinical implications, we performed an explor-
tory subgroup analysis of ACUITY patients with a time from
andomization to start of angiography of4 hours. Similar rela-
ive risk results as in the main analysis justified an approximate
valuation of the 1-vial situation, which yielded superior cost-
ffectiveness results for bivalirudin. Finally, testing the impact of
ncreased use of radial arterial access and conservatively assum-
ng no access site bleedings in these patients, irrespective of an-
icoagulation strategy used, did not affect health economic con-
lusions. In combination, these findings imply that the cost-
ffectiveness of bivalirudin in routine UK practice may be further
mproved over our base case ICER results and that, in some pa-
ient groups, bivalirudin may be dominant.
There are some limitations. QALY gains were based on a
on-significant relative risk of death at 1 year. The ACUITY
rial was not powered to demonstrate a survival advantage,
ut all recent bivalirudin trials trended to improved mortality,
ore distinctly so in patients who also received a thienopyri-
ine [2–4]. Probabilistic sensitivity analysis is the appropriate
ethodology to correctly incorporate and assess the impact of
uch parameter uncertainty arising from clinical trial results
32]. In the GRACE-based analysis, a substantial proportion of
atients in the comparator strategy received heparin only, but
ivalirudin was assumed to be used in all patients in this pro-
ection. Relative risks were not adjusted for increased cardio-
ascular risk or decreased bleeding risk in those GRACE pa-
ients who received heparin only, because of lack of suitable
ata. For similar reasons, relative risks and costs were not
orrected for lack of thienopyridine treatment in 12% of the
ncluded GRACE patients. In the absence of suitable input
ata, the modeling did not link long-term survival and cost to
isk changes in other clinical events or to the occurrence of
Is or bleeds during the first year. Because of a lack of quality
leeding cost data, we relied on a comparison of the impact of
leeds and PCI procedures on hospitalization costs, as as-
essed by multivariate regression analyses [24,25]. No disutil-
ty was applied to patients with bleeding complications. Given
lack of longer-term data, we assumed equal average life ex-
ectancy of 1-year survivors in both strategies. Some advan-
ages of bivalirudin with a potential for economic impact, such
s reduced anticoagulation monitoring requirements, were
ot taken into account in the modeling.
Bivalirudin has been shown to efficiently reduce the occur-
ence of access site and organ bleeds in NSTE-ACS patients and
elated patient populations [1,3,4]. This has economic as well as
linical implications. An association of major bleeds with mor-
ality has been reported [33]. In planned PCI and in the ACUITY
atients who received a thienopyridine before or after PCI, bi-
alirudin trended to improved mortality [2,3]. Consistent with
hese findings, a statistically significant survival effect at 30 days
nd at 1 year was observed in the Harmonizing Outcomes with
evascularization and Stents in Acute Myocardial Infarction trial
f acute MI patients undergoing primary PCI [4,5]. A large, retro-pective US database study of nearly 130,000 patients undergo-
ng inpatient PCI confirmed the repeatability of the effects on
leeds and survival in routine practice [34].
From a United Kingdom NHS perspective, bivalirudin is
ikely to be cost-effective in NSTE-ACS patients who are at a
oderate to high risk of major cardiovascular events, undergo
arly or urgent invasive management otherwise involving GPI
se, and receive a thienopyridine.
upplementary Data
upplementary data associated with this article can be found,
n the online version, at 10.1016/j.jval.2010.10.025.
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